VRTXVertex Pharmaceuticals, Inc.
$479.00
$1.50
(0.31%)
Closed $482.00
$3.00
(0.62%)
After Hours
EarningsAug 3
Mkt Cap$121.95B
Vol1.11M
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up PR Newswire LAS VEGAS, July 21, 2026 Issued on behalf of Ava Bio, Inc. (OTCQB: AVAI)LAS...
PR Newswire
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.
Zacks
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
Key PointsVertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual sales potential...
Nasdaq News: Markets
Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?
NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, strengthening its nephrology portfolio.
Zacks
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals has a marketread more...
Benzinga
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.
Zacks
If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Zacks
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Key PointsVertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated into billion-dollar earnings...
Nasdaq News: Markets
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest VRTX News
ViewA Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
PR Newswire
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
Zacks
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
Nasdaq News: Markets
Advertisement|Remove ads.